243 related articles for article (PubMed ID: 24845012)
1. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
John A; Michel MS
Urologe A; 2014 Jun; 53(6):893-902; quiz 903. PubMed ID: 24845012
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
3. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
6. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
7. Bleeding and antidotes in new oral anticoagulants.
Majeed A; Schulman S
Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
[TBL] [Abstract][Full Text] [Related]
8. Perioperative management of patients on new oral anticoagulants.
Lai A; Davidson N; Galloway SW; Thachil J
Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
10. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
[TBL] [Abstract][Full Text] [Related]
11. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Blann AD
Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
13. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Kornej J; Potpara T; Lip GY
Pol Arch Med Wewn; 2013; 123(11):623-34. PubMed ID: 24104195
[TBL] [Abstract][Full Text] [Related]
15. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants in atrial fibrillation.
Noll G; Noll S; Hürlimann D
Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
[TBL] [Abstract][Full Text] [Related]
17. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Lazo-Langner A; Lang ES; Douketis J
Crit Care; 2013 Jun; 17(3):230. PubMed ID: 23806169
[TBL] [Abstract][Full Text] [Related]
18. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
19. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Levy JH
Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
[TBL] [Abstract][Full Text] [Related]
20. The laboratory and the new oral anticoagulants.
Tripodi A
Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]